These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 25297768)

  • 21. Bortezomib plus melphalan and prednisone for multiple myeloma.
    Avvisati G
    N Engl J Med; 2008 Dec; 359(24):2613; author reply 2613-4. PubMed ID: 19090032
    [No Abstract]   [Full Text] [Related]  

  • 22. A new standard of care in newly diagnosed multiple myeloma.
    Richardson PG
    Lancet; 2010 Dec; 376(9758):2043-4. PubMed ID: 21146204
    [No Abstract]   [Full Text] [Related]  

  • 23. Novel therapies in multiple myeloma for newly diagnosed nontransplant candidates.
    Kristinsson SY; Landgren O; Rajkumar VS
    Cancer J; 2009; 15(6):473-8. PubMed ID: 20010166
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial.
    Mateos MV; Oriol A; Martínez-López J; Gutiérrez N; Teruel AI; de Paz R; García-Laraña J; Bengoechea E; Martín A; Mediavilla JD; Palomera L; de Arriba F; González Y; Hernández JM; Sureda A; Bello JL; Bargay J; Peñalver FJ; Ribera JM; Martín-Mateos ML; García-Sanz R; Cibeira MT; Ramos ML; Vidriales MB; Paiva B; Montalbán MA; Lahuerta JJ; Bladé J; Miguel JF
    Lancet Oncol; 2010 Oct; 11(10):934-41. PubMed ID: 20739218
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Myeloma presenting during pregnancy.
    Smith D; Stevens J; Quinn J; Cavenagh J; Ingram W; Yong K
    Hematol Oncol; 2014 Mar; 32(1):52-5. PubMed ID: 23996410
    [No Abstract]   [Full Text] [Related]  

  • 26. Advances in therapy of multiple myeloma.
    Bladé J; Rosiñol L
    Curr Opin Oncol; 2008 Nov; 20(6):697-704. PubMed ID: 18841053
    [TBL] [Abstract][Full Text] [Related]  

  • 27. "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.
    Gasparetto C; Gockerman JP; Diehl LF; de Castro CM; Moore JO; Long GD; Horwitz ME; Keogh G; Chute JP; Sullivan KM; Neuwirth R; Davis PH; Sutton LM; Anderson RD; Chao NJ; Rizzieri D
    Biol Blood Marrow Transplant; 2010 Jan; 16(1):70-7. PubMed ID: 19733251
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Chemotherapy for multiple myeloma].
    Ishida T
    Nihon Rinsho; 2007 Dec; 65(12):2280-4. PubMed ID: 18069273
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.
    Palumbo A; Bringhen S; Larocca A; Rossi D; Di Raimondo F; Magarotto V; Patriarca F; Levi A; Benevolo G; Vincelli ID; Grasso M; Franceschini L; Gottardi D; Zambello R; Montefusco V; Falcone AP; Omedé P; Marasca R; Morabito F; Mina R; Guglielmelli T; Nozzoli C; Passera R; Gaidano G; Offidani M; Ria R; Petrucci MT; Musto P; Boccadoro M; Cavo M
    J Clin Oncol; 2014 Mar; 32(7):634-40. PubMed ID: 24449241
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Thalidomide, cyclophosphamide and dexamethasone induction therapy: feasibility for myeloma patients destined for autologous stem cell transplantation.
    Chang WJ; Kang ES; Lee ST; Kim SH; Kim DW; Kim SJ; Kim K
    Acta Haematol; 2014; 132(2):226-32. PubMed ID: 24732093
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.
    Palumbo A; Attal M; Roussel M
    Clin Cancer Res; 2011 Mar; 17(6):1253-63. PubMed ID: 21411441
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cutaneous involvement in multiple myeloma and bortezomib.
    Siniscalchi A; Fratoni S; Santeusanio G; Del Poeta G; de Fabritiis P; Caravita T
    Ann Hematol; 2009 Nov; 88(11):1137-9. PubMed ID: 19259673
    [No Abstract]   [Full Text] [Related]  

  • 33. Update on recent developments for patients with newly diagnosed multiple myeloma.
    Palumbo A; Magarotto V; Gay F; Falco P; Bringhen S; Boccadoro M
    Ann N Y Acad Sci; 2008 Sep; 1138():19-21. PubMed ID: 18837878
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Complications and managements in treatment of melphalan, prednisone and new agents].
    Ishida T
    Nihon Rinsho; 2015 Feb; 73 Suppl 2():649-52. PubMed ID: 25831841
    [No Abstract]   [Full Text] [Related]  

  • 35. DKK1 correlates with response and predicts rapid relapse after autologous stem cell transplantation in multiple myeloma.
    Lemaire O; Attal M; Bourin P; Laroche M
    Eur J Haematol; 2010 Mar; 84(3):276-7. PubMed ID: 19891699
    [No Abstract]   [Full Text] [Related]  

  • 36. Front-line lenalidomide therapy in patients with newly diagnosed multiple myeloma.
    Cejalvo MJ; de la Rubia J
    Future Oncol; 2015; 11(11):1643-58. PubMed ID: 25857329
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I trial of first-line bortezomib/thalidomide plus chemotherapy for induction and stem cell mobilization in patients with multiple myeloma.
    Badros A; Goloubeva O; Fenton R; Rapoport AP; Akpek G; Harris C; Ruehle K; Westphal S; Meisenberg B
    Clin Lymphoma Myeloma; 2006 Nov; 7(3):210-6. PubMed ID: 17229337
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Post-transplantation consolidation and maintenance therapy with lenalidomide for Japanese patients with multiple myeloma.
    Takamatsu H; Munemoto S; Murata R; Terasaki Y; Nakajima K; Nakao S
    Anticancer Res; 2013 Dec; 33(12):5681-5. PubMed ID: 24324117
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Correlation between burden of 17P13.1 alteration and rapid escape to plasma cell leukaemia in multiple myeloma.
    Mangiacavalli S; Pochintesta L; Cocito F; Pompa A; Bernasconi P; Cazzola M; Corso A
    Br J Haematol; 2013 Aug; 162(4):555-8. PubMed ID: 23718846
    [No Abstract]   [Full Text] [Related]  

  • 40. SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma.
    Barosi G; Merlini G; Billio A; Boccadoro M; Corradini P; Marchetti M; Massaia M; Tosi P; Palumbo A; Cavo M; Tura S
    Ann Hematol; 2012 Jun; 91(6):875-88. PubMed ID: 22476884
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.